承诺函 宁夏中科生物科技股份有限公司(以下简称"宁科生物") 控股股东上海中能企业发展(集团)有限公司(以下简称"上海 中能")拟受让债权人广东鸿俊投资有限公司(以下简称"广东鸿 俊")对宁科生物的债权 5.6 亿元,并豁免宁科生物 5.6 亿元债务。 此外,宁科生物为广东南粤银行股份有限公司(以下简称"南粤 银行"）向广东鸿俊提供的5亿元贷款提供担保,南粤银行已向 法院提起诉讼要求债务人广东鸿俊及宁科生物等担保人依法承担 清偿责任。 如宁科生物因对广东鸿俊向南粤银行的借款提供违规担保, 而最终需承担部分或全部责任,我司将代替宁科生物直接承担其 应实际承担的还款、执行质押物或赔偿责任,并承诺不向宁科生 物追索。 本承诺不附条件、不可撤销。 特此承诺。 湖南醇投 二〇二四年 针对前述两个问题,我司作为宁科生物意向投资人,为保护 宁科生物、股东和债权人等各方合法权益,特公开承诺如下: 如果广东鸿俊的债权转让行为及上海中能对宁科生物的债务 豁免行为最终被撤销,导致该 5.6亿元债务未能全部豁免,或导 致宁科生物需对上述债务履行清偿责任,我司将代替宁科生物直 接承担其应实际承担的债务清偿责任,并承诺不向宁科生物追索。 ...

证券代码：600165 股票简称：*ST 宁科 公告编号：临 2024-181 宁夏中科生物科技股份有限公司 关于前期会计差错更正及追溯调整的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 宁夏中科生物科技股份有限公司（以下简称：公司或宁科生物）本次会计 差错更正事项是对2022—2023年度、2024年半年度和2024年三季度财务报表及相 关附注进行追溯调整，其影响涉及营业收入、营业成本以及归属于上市公司股东 的净利润等相关财务数据。 ● 根据中国证监会《公开发行证券的公司信息披露编报规则第19号——财务 信息的更正及相关披露》的相关规定，公司已聘请会计师事务所对2022年度报告 中涉及的财务信息进行了调整，并追溯调整2022年—2023年财务报表，同时出具 《关于宁夏中科生物科技股份有限公司前期差错更正专项说明的审核报告》与本 公告披露之日一并披露。 ● 公司及实际控制人虞建明先生于2024年10月30日收到中国证券监督管理 委员会下发的两份《立案告知书》（编号：证监立案字0342024005号、 ...

Financial Performance - The company reported a net profit of -632,343,541.87 CNY for 2023, leading to a cumulative profit available for distribution to shareholders of -839,052,659.21 CNY, resulting in no profit distribution for the year [3]. - Operating revenue decreased by 52.74% to 285,688,730.55 CNY in 2023 from 604,539,544.17 CNY in 2022 [15]. - The net loss attributable to shareholders was -464,709,294.14 CNY, compared to -210,984,106.46 CNY in the previous year [15]. - The net cash flow from operating activities was 23,154,120.04 CNY, down 56.43% from 53,144,180.21 CNY in 2022 [15]. - The company’s net assets attributable to shareholders decreased by 82.29% to 99,156,760.51 CNY at the end of 2023 from 559,810,051.25 CNY at the end of 2022 [15]. - The net profit attributable to shareholders for the entire year was CNY -245,281,273.74, indicating a significant loss compared to previous years [44]. - The company experienced a net cash flow from operating activities of CNY 53,673,948.17 in Q4 2023, a recovery from negative cash flow in earlier quarters [44]. - The company has been issued a risk warning by the Shanghai Stock Exchange due to consecutive years of negative net profit and uncertainty regarding its ability to continue as a going concern [35]. - The company’s financial report for 2023 received a disclaimer of opinion from its auditor, raising concerns about the reliability of its financial statements [35]. - The company incurred financial expenses of 141.86 million RMB, an increase of 58.24% compared to the previous year [67]. Production and Sales - The company reported a total revenue of CNY 117,079,801.29 for Q4 2023, with a year-over-year decrease in sales volume of 83.48% for long-chain dicarboxylic acid [29]. - The company’s total production volume for long-chain dicarboxylic acid was 2,189 tons, reflecting an 80.90% decrease from the previous year [29]. - The active carbon segment saw a sales volume increase of 2.95% year-over-year, with total sales reaching 17,116.45 tons [29]. - Sales in the domestic market dropped by 49.65%, while international sales increased by 2.06% [64]. - The production of long-chain dicarboxylic acid decreased by 80.90%, with sales down by 83.48% [65]. - Revenue from long-chain dicarboxylic acid decreased by 85.82% compared to the previous year, with a corresponding decrease in operating costs by 54.77% [53]. Research and Development - The total R&D investment amounted to 13,873,396.61 CNY, representing 4.86% of total revenue [55]. - The company is currently developing a new fermentation control process to enhance acid production efficiency and reduce costs [57]. - The company has completed the research on a new centrifugal separation technology for long-chain dicarboxylic acid purification [57]. - The company is actively working on multiple R&D projects, including the development of activated carbon products for various applications [57]. - The company has 52 R&D personnel, accounting for 7.11% of the total workforce [76]. - Research and development expenses were reduced by 45.61%, totaling 13.87 million RMB [62]. Market Strategy and Future Plans - The company is focusing on the production of long-chain dicarboxylic acids using a microbial fermentation method, which is expected to dominate the market due to its environmentally friendly production process [22]. - The company plans to increase the localization rate of raw materials and equipment in response to uncertainties from the US-China trade war, which is expected to boost the market share of long-chain dicarboxylic acids [22]. - The company plans to address operational challenges and explore potential restructuring options in response to financial difficulties [35]. - The company plans to implement new strategies for market expansion and product development in the upcoming fiscal year [83]. - The company established a relief plan with local government, with a scale not exceeding 80 million RMB, aimed at restoring production [74]. - The company plans to extend the relief plan until December 31, 2024, to support production recovery [74]. Asset Management and Liabilities - Total current assets as of December 31, 2022, amounted to CNY 250,949,859.47, with cash and cash equivalents at CNY 89,483,876.89 [123]. - Non-current assets totaled CNY 3,026,839,472.43 as of December 31, 2022, with long-term equity investments at CNY 672,169,248.83 [124]. - Total liabilities reached CNY 1,642,829,916.86 in current liabilities, including short-term borrowings of CNY 331,340,167.81 [124]. - The total assets of the company were CNY 3,277,789,331.90 as of December 31, 2022, reflecting a stable asset base [124]. - The company maintained a total of CNY 1,916,141,876.54 in long-term equity investments as of January 1, 2023 [126]. - The total liabilities and equity ratio indicates a balanced financial structure, supporting future growth strategies [124]. Impairment and Provisions - The company recognized an impairment loss of CNY 1,585,164.00 due to asset impairment testing in 2023 [99]. - The total bad debt provision at the end of the period was ¥1,651,462.08, with ¥513,249.56 recognized during the period [140]. - The company recognized an impairment loss of CNY 18.5717 million on its talent apartment assets, reflecting a 12.41% decrease in market value [150]. - The impairment provision for investment properties amounted to CNY 10.7578 million, while the provision for fixed assets was CNY 7.8139 million [150]. - The total amount of fixed assets impairment provisions reached CNY 16,933,676.00, with a book value of CNY 72,789,816.30 [158]. - The impairment provision increased by CNY 64,463,400.99 during the period, bringing the total impairment provision to CNY 66,159,062.08 [183]. Customer and Supplier Concentration - The top five customers contributed 7,520.28 CNY in sales, accounting for 24.14% of total annual sales [54]. - The top five suppliers accounted for 47.77% of total annual purchases, with the largest supplier contributing 14.53% [54]. - The top five accounts receivable contributed to 40.28% of the total accounts receivable and contract assets, with a total of ¥26,046,141.33 [133].

证券代码：600165 股票简称：*ST 宁科 公告编号：临 2024-183 宁夏中科生物科技股份有限公司 第九届监事会第十六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 本次监事会应到监事 3 名，实到监事 3 名。 ● 本次监事会共两项议案，经审议全部通过。 一、监事会会议召开情况 （一）本次监事会召开符合有关法律、行政法规、部门规章、规范性文件和 《宁夏中科生物科技股份有限公司章程》的规定。 （二）本次监事会通知于 2024 年 12 月 21 日以电子邮件方式送达，会议材 料于 2024 年 12 月 23 日以电子邮件方式送达。 （三）本次监事会于 2024 年 12 月 26 日下午 6:00 以现场方式召开。 （四）本次监事会应到监事 3 名，实到监事 3 名。 （五）本次监事会由监事会主席韩存在先生主持。 二、监事会会议审议情况 与会监事对提交本次会议的两项议案进行了认真审议，表决情况如下： （一）审议《关于宁夏中科生物科技股份有限公司会计差错更正的议案》 议案内容详见宁 ...

Financial Performance - The company's operating revenue for Q3 2024 was ¥71,030,635.58, representing a year-on-year increase of 6.62%[3]. - The net profit attributable to shareholders for Q3 2024 was -¥54,577,412.00, with a year-to-date net profit of -¥479,541,476.01[3]. - The basic earnings per share for Q3 2024 was -¥0.080, compared to -¥0.700 for the year-to-date period[3]. - The company reported a net loss of approximately ¥498.93 million for the third quarter of 2024, compared to a net loss of ¥247.88 million in the same period of 2023, indicating a significant increase in losses[49]. - The company’s total profit for the third quarter of 2024 was approximately -¥498.72 million, compared to -¥248.49 million in the same quarter of 2023[49]. - Total comprehensive income attributable to the parent company was -473,510,322.34 CNY, compared to -220,193,861.07 CNY in the same period last year, reflecting a significant decline[71]. - Basic and diluted earnings per share were both -0.700 CNY, compared to -0.322 CNY in the previous year[71]. Assets and Liabilities - Total assets at the end of Q3 2024 were ¥2,212,801,533.90, a decrease of 25.18% compared to the end of the previous year[23]. - The equity attributable to shareholders was -¥418,468,199.54, reflecting a significant decrease of 522.03% year-on-year[23]. - The company's total assets decreased from CNY 2,957,514,548.54 as of December 31, 2023, to CNY 2,212,801,533.90 as of September 30, 2024, representing a decline of approximately 25%[68]. - The company's non-current liabilities decreased from CNY 770,789,590.60 to CNY 573,505,023.42, a reduction of approximately 25.6%[70]. - The company's short-term borrowings decreased from CNY 343,795,810.07 to CNY 227,696,366.09, a decline of about 34%[69]. Cash Flow - The company reported a net cash flow from operating activities of -¥5,958,333.66 year-to-date, indicating ongoing financial challenges[3]. - The net cash flow from operating activities increased significantly due to higher cash receipts from the sale of goods by the subsidiary Ningxia Huahui Environmental Protection Technology Co., Ltd.[27]. - Cash inflow from operating activities totaled 147,286,673.18 CNY, down from 155,827,411.44 CNY year-over-year[80]. - Net cash flow from operating activities was -5,958,333.66 CNY, an improvement from -30,519,828.13 CNY in the same period last year[80]. - Cash inflow from financing activities was 41,600,000.00 CNY, a decrease from 287,531,028.61 CNY in the previous year[80]. - Cash inflow from investment activities was 2,498,855.85 CNY, significantly higher than 290,108.00 CNY in the previous year[80]. - The company reported a decrease in cash received from sales of goods and services, totaling 140,378,435.57 CNY compared to 144,945,878.62 CNY in the previous year[79]. - The company’s cash and cash equivalents decreased by ¥12.21 million in the third quarter of 2024, with a closing balance of ¥9.63 million[52]. Restructuring and Recovery Efforts - The company has applied for reorganization and pre-reorganization due to significant solvency issues, indicating potential restructuring efforts[18]. - The company signed a cooperation agreement with local government platforms to provide ¥45 million in financial support for its subsidiary's recovery efforts[16]. - The company and Zhongke New Materials received a notice from the Shizuishan Intermediate Court regarding a restructuring application due to inability to repay debts, with a pre-restructuring process initiated[32]. - The court approved the initiation of pre-restructuring for the company and Zhongke New Materials on May 30, 2024, and appointed a temporary administrator[34]. - The temporary administrator is actively recruiting and selecting restructuring investors, with a deadline for submissions set for June 28, 2024[35]. - The restructuring process for Zhongke New Materials includes a creditor meeting scheduled for November 6, 2024, to discuss the restructuring plan[62]. - Zhongke New Materials was ordered to undergo restructuring by the court on September 6, 2024, with a liquidation team appointed to manage the process[36]. - The company remains the controlling shareholder of Zhongke New Materials and retains voting rights in the restructuring process, which is part of a coordinated restructuring plan with subsidiaries[40]. Operational Challenges - The company is currently in a temporary production halt, with uncertainty regarding the resumption of normal operations[65]. - The company has faced continuous operating losses for three consecutive years from 2021 to 2023, leading to additional risk warnings regarding its stock listing status[44]. - The company has been placed under delisting risk warning by the Shanghai Stock Exchange effective April 30, 2024, due to an audit report that could not express an opinion[65]. - The company faces potential bankruptcy risks if the court does not approve its restructuring application[64]. - The company’s financial expenses increased to approximately ¥111.71 million in the third quarter of 2024, compared to ¥99.70 million in the same period of 2023[49]. - The company’s research and development expenses were approximately ¥9.92 million in the third quarter of 2024, slightly up from ¥9.84 million in the same period of 2023[49]. Production and Sales - The company is undergoing production recovery at its subsidiary, Ningxia Zhongke New Materials Co., Ltd., which has led to increased trial production and sales volumes[9]. - The company’s major subsidiary, Zhongke New Materials, was temporarily suspended from production starting February 7, 2024, with a low production output during trial production after resuming on April 28, 2024[29]. - The company signed a supplementary agreement on April 9, 2024, extending the support period for Zhongke New Materials until December 31, 2024[31]. - The total revenue for the first three quarters of 2024 was CNY 184,527,070.49, compared to CNY 168,608,929.26 for the same period in 2023, indicating a growth of about 9.5%[70]. - The total operating costs decreased from CNY 397,869,702.37 to CNY 352,868,998.74, a reduction of approximately 11.3%[70].

Financial Performance - The company achieved operating revenue of 371 million RMB and a net profit of -202 million RMB during the reporting period [50]. - The revenue from chemical raw materials and products manufacturing was 237 million RMB, with a net profit of -25.63 million RMB, impacted by low downstream demand and rising raw material prices [50]. - The company reported a total of CNY 34,960,460.22 in investment income from long-term equity investments, a decrease from CNY 39,771,498.01 in the previous period [88]. - The company's main business revenue for the current period is CNY 604,539,544.17, with a cost of CNY 604,030,284.29, compared to CNY 248,717,404.89 in revenue and CNY 330,631,103.93 in cost for the previous period [80]. - The net profit attributable to the parent company for the current period is CNY -210,984,106.46, compared to CNY -166,087,675.85 in the previous period [88]. - The company reported a net loss attributable to shareholders for 2022 of approximately ¥210.98 million, compared to a loss of ¥166.09 million in 2021 [127]. - The total profit for the current period is CNY -242,972,366.09, with income tax expenses amounting to CNY 4,358,496.05 [95]. Assets and Liabilities - The total balance of short-term and long-term liabilities reached ¥638,678,103.04, compared to ¥407,875,811.50 previously, marking a significant increase of approximately 56.5% [28]. - The total balance of fixed assets was RMB 395,507,389.33, with ongoing procedures for property rights certification [16]. - The total balance of contract liabilities at the end of the period was ¥10,462,084.04, compared to ¥2,095,223.17 at the beginning, showing an increase of approximately 399.5% [31]. - The total deductible losses reported were approximately 573.9 million RMB, an increase from 390.9 million RMB in the previous year [54]. - The total assets at the end of 2022 were approximately ¥3.28 billion, a decrease of 0.85% from the previous year [127]. Cash Flow - The net cash inflow from investment activities amounted to ¥14,112,837.30, while the cash outflow was ¥7,004,900.00, resulting in a net cash flow of ¥7,112,837.30 from investment activities [159]. - The total cash inflow from financing activities reached ¥375,805,741.67, with cash outflows totaling ¥373,710,101.06, leading to a net cash flow of ¥2,095,640.61 from financing activities [159]. - The company's cash and cash equivalents increased by ¥1,756,291.90, ending the period with a balance of ¥1,904,716.80 [159]. Government Subsidies and Taxation - The total amount of government subsidies rose to ¥19,904,441.28, up from ¥12,913,902.88, representing an increase of about 54.5% [47]. - Government subsidies received in the current period total CNY 1,843,000.00, up from CNY 700,000.00 in the previous period [92]. - The company's total tax liabilities at the end of the period amounted to ¥8,288,307.25, compared to ¥4,780,828.51 at the beginning, showing an increase of approximately 73.5% [34]. Research and Development - The company has completed several R&D projects, including new fermentation processes for lauric acid, which aim to reduce costs and improve yield [143]. - Ongoing R&D projects include the development of activated carbon for acetone adsorption, achieving an adsorption rate of 22% [143]. - The company is developing a new generation of bio-based lauric acid production technology aimed at improving efficiency and reducing costs [172]. - The new generation of bio-based long-chain dicarboxylic acid production technology has improved fermentation efficiency beyond design levels, significantly reducing production costs and waste emissions [199]. Market Position and Strategy - The company is positioned in the bio-based materials manufacturing sector, which is gaining market dominance due to its environmentally friendly production methods [51]. - The company has plans for market expansion and new product development, although specific financial figures were not disclosed in the provided content [49]. - The company is focused on expanding its market presence for long-chain dicarboxylic acid production, utilizing a solvent-free process that aligns with national environmental policies [167]. - The company has established a mixed sales model combining direct sales, distribution, and consignment to enhance profitability and market reach [167]. Operational Efficiency - The company adopts a "sales-driven production" model for raw material procurement, ensuring efficient inventory management and cost control [198]. - Continuous technological research and application have led to a decrease in production costs and improved resource utilization efficiency [199]. - The production process is designed to be environmentally friendly, with no use of powdered activated carbon or organic solvents, aligning with low-carbon and sustainable development trends [199]. Employee and Management Expenses - Employee compensation increased significantly to ¥39,592,886.71 from ¥22,633,043.49, representing a growth of 74.8% [111]. - Management expenses increased by 199.55% year-on-year, primarily due to losses from the subsidiary's project suspension and increased capitalized salaries [178]. - Financial expenses rose by 186.81% year-on-year, largely due to increased capitalized interest from the subsidiary's construction projects [178].

证券代码：600165 股票简称：*ST 宁科 公告编号：临 2024-180 宁夏中科生物科技股份有限公司 第九届董事会第三十七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 本次董事会应到董事 7 名，实到董事 7 名。 ● 本次董事会共两项议案，经审议全部获得通过。 一、董事会会议召开情况 （一）本次董事会召开符合有关法律、行政法规、部门规章、规范性文件和 《宁夏中科生物科技股份有限公司章程》的规定。 （二）本次董事会通知于 2024 年 12 月 21 日以微信和电子邮件方式送达， 会议材料于 2024 年 12 月 23 日以电子邮件方式送达。 （三）本次董事会于 2024 年 12 月 26 日下午 5:30 以现场结合通讯方式召 开。 （四）本次董事会应到董事 7 名，实到董事 7 名。 （五）本次董事会由董事长胡春海先生主持，全体监事及高级管理人员列席 了会议。 二、董事会会议审议情况 与会董事对提交本次会议的两项议案进行了认真审议，表决情况如下： （一）审议《关于宁夏中科生 ...

证券代码：600165 股票简称：*ST 宁科 公告编号：临 2024-185 宁夏中科生物科技股份有限公司 关于重整及预重整事项的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容及风险提示： ● 截至本公告披露日，宁夏中科生物科技股份有限公司（以下简称：公司 或宁科生物）除已披露的被申请重整及预重整、子公司宁夏中科生物新材料有限 公司（以下简称：中科新材）被法院裁定进行重整的事项外，未发生该事项相关 进展。 ● 公司 2024 年前三季度实现归属于上市公司股东的净利润为-47,954.15 万 元，亏损同比增加 25,931.67 万元；2024 年前三季度实现归属于上市公司股东扣 除非经常性损益后的净利润为-45,686.02 万元，亏损同比增加 24,463.52 万元； 2024 年三季度实现归属于上市公司股东的净资产为-34,976.52 万元，期末净资产 为负。 ● 中科新材进入重整程序，重整能否成功存在不确定性，如法院最终裁定 中科新材重整不成功，将存在被法院宣告破产的风险，公司将可能失去对中科 ...

证券代码：600165 股票简称：*ST 宁科 公告编号：临 2024-182 宁夏中科生物科技股份有限公司 关于接受控股股东债务豁免暨关联交易公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 截至本公告披露日，宁夏中科生物科技股份有限公司（以下简称：宁科生 物或公司）整体债务规模为 18.05 亿元、其中逾期债务总规模为 16.02 亿元，涉 诉债务规模为 18.24 亿元，除子公司宁夏华辉环保科技股份有限公司（以下简称： 华辉环保）及其全资子公司宁夏天福活性炭有限公司（以下简称：宁夏天福）的 银行账户外，公司、宁夏新日恒力国际贸易有限公司（以下简称：恒力国贸）及 华辉环保活性炭分公司大部分银行账户被冻结。虽宁夏中科生物新材料有限公 司（以下简称：中科新材）银行账户已全部解冻，但公司目前严重缺乏用于偿债 的资金和流动资产，结合目前债务风险巨大的情况，公司持续经营能力面临严重 的负面影响，不能清偿到期债务且明显缺乏清偿能力，具备破产原因。 ● 公司 2024 年前三季度实现归属于上市公司股东的净利润为- ...

证券代码：600165 股票简称：*ST 宁科 公告编号：临 2024-184 宁夏中科生物科技股份有限公司 关于子公司签署《债务豁免协议》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 截至本公告日，宁夏中科生物科技股份有限公司（以下简称：公司或宁科 生物）控股子公司宁夏中科生物新材料有限公司（以下简称：中科新材）欠德 运新企业管理咨询（乐清）合伙企业（有限合伙）（以下简称：德运新）债务本 金 7,118 万元，利息 9,706,817.80 元，合计本息 80,886,817.80 元。 2024 年 12 月 26 日，中科新材与德运新签署《债务豁免协议》，德运新同 意对该笔债务进行无条件豁免。 一、《债务豁免协议》主要内容 甲方：德运新企业管理咨询（乐清）合伙企业（有限合伙） 地址：浙江省温州市乐清市城东街道旭阳路 6698 号 执行事务合伙人：杨超 乙方：宁夏中科生物新材料有限公司 地址：石嘴山市惠农区河滨街中央大道与恒力大道交叉路口西北侧（原石 嘴山市第二十三小学） 法定代表人：胡春海 以上单称"一方"，合 ...